Tactile Systems Technology Q2 2026 Earnings Report

Tactile Systems Technology EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.14
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Tactile Systems Technology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $85.52 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Tactile Systems Technology Announcement Details

• Quarter: Q2 2026
• Date: 8/3/2026
• Time: After Market Closes
• Conference Call Date: Monday, August 3, 2026
• Conference Call Time: 5:00PM ET

Tactile Systems Technology (NASDAQ:TCMD), headquartered in Plymouth, Minnesota, is a medical device company specializing in the design, manufacture and marketing of home-use pneumatic compression therapy systems for the treatment of lymphedema and other chronic edema-related conditions. Using proprietary software and patented pump technologies, the company’s platforms are designed to improve patient outcomes through sequential pressure treatment that promotes fluid mobilization and enhanced lymphatic function.

At the core of Tactile Systems’ product portfolio is the Flexitouch® system, a programmable pneumatic pump and garment system approved for home use, and the Aria® device, which features an intuitive touchscreen interface and advanced garment design. In addition to the therapy pumps and garments, the company offers a range of patient accessories, digital patient monitoring software and clinical training programs to support healthcare providers and ensure adherence to therapy protocols. These comprehensive solutions aim to reduce complications, such as infections or ulcerations, and improve quality of life for patients managing chronic conditions.

Founded in the mid-2000s, Tactile Systems Technology completed its initial public offering in 2013 and has since focused on expanding its commercial presence across the United States, with select distribution partnerships in Canada and international markets. The company’s field organization includes clinical specialists who collaborate with physicians, therapists and home health agencies to integrate pneumatic compression therapy into standard care pathways. Under the leadership of President and Chief Executive Officer Steve Lo, Tactile Systems continues to invest in clinical research and product innovation to broaden its portfolio and address unmet patient needs in lymphatic health management.